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Abstract
Mitochondria as an important organ in eukaryotic cells produced energy through oxidative phosphorylation and
also played an important role in regulating the apoptotic signal transduction process. Importantly, mitochondria like
nuclei also contained the functional DNA and were very sensitive to anticancer drugs which could effectively inhibit
the synthesis of nucleic acid, especially the production of DNA. In this work, we designed novel triphenyl phosphine
(TPP)-conjugated chitosan (CS) nanoparticles (NPs) for efficient drug delivery to cell mitochondria. The results showed
that compared with free doxorubicin (Dox), Dox-loaded TPP-NPs were specifically distributed in mitochondria of tumor
cells and interfered with the function of mitochondria, thus resulted in the higher cytotoxicity and induced
the significant cell apoptosis effect. Taken together, triphenyl phosphine-conjugated chitosan nanoparticles
may become a promising mitochondria-targeting nanocarrier candidate for enhancing antitumor effects.
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Background
Doxorubicin (Dox) was an anthracycline glycoside anti-
biotic drug derived by chemical semisynthesis from a
bacterial species and widely clinically used in the hydro-
chloride form. It was commonly used in the treatment
of a wide range of cancers, including hematological ma-
lignancies (blood cancers, like leukemia and lymphoma),
many types of carcinoma (solid tumors), and soft tissue
sarcomas [1–6]. Although Dox effectively killed tumor
cells and showed the excellent clinical effect in the treat-
ment of cancer, significant systemic adverse reactions
were also emerged such as bone marrow suppression,
congestive heart failure, and typhlitis [7–11]. Especially,
after a time period of drug exposure, the treatment
response to chemotherapy in some patients was highly
declined due to an effect known as acquired resistance
[12, 13]. Therefore, it was necessary to find an efficient
treatment strategy on the application of Dox for enhancing
cytotoxicity to tumor tissues and overcoming drug
resistance. In recent years, liposomal Dox (liposome
doxorubicin) and Dox-loaded nanoparticles enhanced
the intracellular accumulation of Dox or changed the
cellular distribution of drug, thus strengthening the
cytotoxicity of anticancer drugs and limiting the car-
diotoxicity of Dox [14–20]. Mitochondria as the main
provision of cellular power played a vital role on cell
survival and death, and it not only produced most
ATP which the cell metabolism required but also regu-
lated metabolism and programmed cell death. Some anti-
cancer drugs directly interfered with mitochondrion
respiratory chains and eventually led to tumor cell death
[21]. Therefore, dysfunction of mitochondria would be a
preferential target of many antineoplastic agents [22–25].
It was reported that the anticancer drug Dox-loaded
nanocarrier delivered Dox to mitochondria in a targeted
manner to interact with mtDNA, leading to the direct
dysfunction of mitochondria in cancer cells. Accumulation
of Dox in mitochondria generated excessive reactive oxy-
gen species and caused damage to the mitochondrial re-
spiratory chain, further resulting in mitochondrial lipid
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oxidation and increasing release of cytochrome c [26].
Chitosan (CS) was a natural cationic polymer with the ex-
cellent biocompatibility, low toxicity, and especially low
cost compared to other nano carriers. CS had the positive
charges and easily combined with the negatively charged
membrane, facilitating its internalization. As membrane
potential of mitochondria was much higher than other or-
ganelles because of ATP synthesis and ion transport,
therefore, triphenyl phosphine (TPP) as a kind of lipo-
philic cationic compound could be effectively targeted in
mitochondria. Combination of CS and TPP could smartly
target the loaded drug to mitochondria, thus triggering
programmed cell death process, leading to cell stress re-
sponse, cytochrome c release, and then the damage and
cytotoxicity of the tumor cells.
Herein, we designed novel triphenyl phosphine (TPP)-
conjugated chitosan nanoparticles (TPP-CS NPs) for
the targeted mitochondrial delivery of Dox to enhance
antitumor efficiency. Triphenyl phosphine was grafted
onto the surface of (as-prepared) chitosan nanoparticles
for targeting the mitochondria, and Dox was encapsulated
into NPs for investigating the drug loading and in vitro
release process. Furthermore, the cellular distribution, in
vitro cytotoxicity, and cellular apoptosis were also investi-
gated to evaluate cancer treatment efficacy by the targeted




Chitosan (CS) of medium molecular weight (deacetyla-
tion degree, 80%; molecular weight, 400,000) was pur-
chased from Haixin Biological Product Co., Ltd (China);
Dox hydrochloride was purchased from Beijing Huafeng
Lianbo Technology Co., Ltd. (China). 3-(4,5-Dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC),
triphenyl phosphine (TPP), and N-hydroxysuccinimide
(NHS) were obtained from Sigma-Aldrich Co. (St Louis,
MO, USA); A549 cell lines and Hela cells were pur-
chased from the Institute of Biochemistry and Cell Biol-
ogy of Chinese Academy of Sciences (Shanghai, People’s
Republic of China). All other chemicals purchased
were of analytical grade and were obtained from a
variety of vendors.
Preparation and Characterization of Dox-Loaded
TPP-CS NPs
According to the previous reported literature [27], Dox-
loaded triphenyl phosphine-conjugated chitosan nano-
particles were prepared by ionic crosslinking method.
Briefly, 10 mL stock solution of Dox at a concentration
of 1 mg/mL was pre-mixed with CS solution followed by
the addition of sodium tripolyphosphate reserve liquid,
and drug-loaded NPs with the mass ratio of CS and so-
dium tripolyphosphate at 2:1 were formed until the mix-
ture appeared opalescence. TPP was activated by reacting
with EDC and NHS [28] to form semi-stable amine-
reactive HNS-ester at constant vibration for 1 h and was
further conjugated to the surface of NPs by the formation
of stable amide bond. The structure of TPP to CS NPs
was investigated by using affinity-1 infrared spectroscopy
(Shimadzu, Kyoto, Japan). Nanoparticles were dispersed in
distilled water to obtain the homogenous suspension, and
the shapes, sizes, and zeta potentials of the particles were
determined by a transmission electron microscope (JEM-
1200EX; Jeol, Tokyo, Japan) and laser particle analysis
(Nano ZS90; Malvern Instruments, Malvern, UK). The
encapsulation efficiency of Dox in NPs and drug release
characterization in medium with different pH were also
evaluated by a previously reported method [29].
MTT Assay
MTT assay was used to detect antitumor activity of
Dox-loaded TPP-NPs in vitro. Briefly, predetermined
amount of Dox-loaded NPs were added into distilled PBS
buffer at the different volume to obtain a homogenous
suspension. Cells were exposed to suspension of NPs at
different amounts. Hela cells and A549 cells were seeded
in 96-well plates (seeding density was 5 × 104 cells/well)
and cultured to logarithmic growth phase. Next, culture
medium was removed and re-added serum-free medium
respectively containing free Dox and Dox-loaded NPs with
different concentrations of Dox into cells for continuous
incubation for 24 h. Twenty microliters of MTT (5 mg/
mL) was placed into each well to incubate for 4 h followed
by the addition of 150 μL of DMSO in each well for dis-
solving crystal violet precipitation, and the absorbance at
490 nm was detected in a microplate reader.
Intracellular Distribution and Quantitative Analysis of free
Dox and Dox-Loaded TPP-NPs in Cells
In order to investigate the intracellular distribution and
uptake intensity of Dox, free Dox and Dox-loaded TPP-
NPs were chosen to incubate with A549 cells and Hela
cells for observing their internalizing process and quan-
tifying the uptake rate. Briefly, A549 cells and Hela cells
at logarithmic growth phase were treated with 0.25%
trypsin, and after centrifugation, cell suspension was ob-
tained and seeded in six-well plates at a density of 5 ×
104/mL for incubation at 37 °C for 24 h. Then, cells were
treated with free Dox and Dox-loaded TPP-NPs containing
the same amount of Dox for a certain time. The nucleuses
were stained with Hoechst (blue) for 15 min at 37 °C, and
the mitochondria were stained by Mitotracker Green FM.
Their locations were tracked in cells by confocal laser scan-
ning microscopy (FluoView FV10i; Olympus Corporation,
Tokyo, Japan) at given time intervals. Free Dox and Dox-
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loaded TPP-NPs at the same amount of Dox were
treated with both cells, and the intensity of fluorescence
from Dox which was excited at 479 nm and emitted at
587 nm was quantified using a microplate reader. The
relative uptake ratios of free Dox and Dox-loaded TPP-
NPs were determined by calculating the ratio of intra-
cellular fluorescent intensity from internalized free Dox
and Dox-loaded TPP-NPs to the initial fluorescent in-
tensity from the total added free Dox and Dox-loaded
TPP-NPs at the different time interval.
Mitochondrial Membrane Potential Change
Cells were digested and seeded into the culture plate to
reach a density at cell coverage of 50–70% followed by
the separate addition of free Dox and Dox-loaded TPP-
NPs. After 24 h, fresh culture medium containing JC-1
at 1 mg/mL was placed into wells and incubated for
30 min at 37 °C under dark conditions. A laser scanning
confocal microscope (FluoView FV10i, Olympus, Japan)
was used to observe the image change of mitochondrial
membrane. JC-1 dye was excited using the 488 nm, and
emission light collection was set to 515–545 nm (green)
and 570–600 nm (red).
Intracellular Reactive Oxygen Species (ROS) Measurement
Free Dox and Dox-loaded TPP-NPs were incubated with
cells for 12, 24, and 48 h followed by the continuous in-
cubation with 10 μM 2,7-dichlorofluorescein diacetate
(DCFH-DA, Sigma, MO, USA) for about 30 min. After
washing with PBS, the intracellular DCF fluorescence in-
tensity which was excited at 485 nm and emitted at
530 nm was detected using a microplate reader (Synery-2,
Biotek, USA) to investigate the extent of oxidative stress.
Cell Apoptosis Evaluation by Western Blot
According to the protocol of our previous study [29],
free Dox and Dox-loaded TPP-NPs were incubated with
cells for 48 h, and then protein supernatant was lysed in
RIPA buffer and separated by SDS-PAGE electrophor-
esis. The protein was transferred from the gel to the
PVDF membrane and blocked with 1% BSA at 4 °C
overnight. The PVDF membrane was incubated with the
primary antibodies (caspase-3, caspase-9, Bax, cyto-
chrome c) at 4 °C overnight, followed by the continuous
incubation with secondary antibody and being stained
with ECL. The levels of the targeted apoptosis proteins
(caspase-3, caspase-9, Bax) and cytochrome c were ana-
lyzed by UVP gel analysis system.
Results
The Preparation and Characteristics of Various Kinds of
NPs
The structural characteristics of the conjugation of TPP
to the surface of CS NPs were investigated using IR. It
was observed in Fig. 1d that compared with the spectra
of the mixture of TPP and CS NPs, the appearance of
two intense and sharp peaks at 1650 and 1540 cm−1 in
the spectra of TPP-NPs indicated that the carboxylic
group of TPP molecules and the amino group of CS NPs
had reacted to form the new formed amide bond. The
particle size and zeta potential of Dox-loaded TPP-NPs
were evaluated by Malvern dynamic laser light scatter-
ing. The results showed that the average particle size of
TPP-NPs was about 100.1 ± 4.3 nm, and the zeta poten-
tial was positive and valued at around 15.6 ± 2.3 mV.
The morphology of TPP-NPs was spherical in shape and
dispersed homogenously with lower polydispersity index
at 0.016. In addition, loading efficiency (LE), encapsula-
tion efficiency (EE), and in vitro drug release were also
explored. The results indicated that the LE and EE of
Dox in TPP-NPs were about 13.2 and 91.3%, respect-
ively. In vitro Dox release experiments (Fig. 1c) indi-
cated that Dox-loaded TPP-NPs showed sustained
release of Dox from nanoparticles and varied markedly
according to the pH gradient. With the decrease of pH
in medium, the releasing rate of Dox was increased and
the cumulative release of drug was significantly en-
hanced, thus enhancing its cytotoxicity in the acidic
tumor microenvironment.
Cellular Viability Study
Cytotoxicities of Dox-loaded TPP-NPs on A549 cells
and Hela cells were determined by MTT. As it could be
seen from Fig. 2, blank TPP-NPs and CS NPs were not
toxic to both cells and the survival rates of TPP-NPs at
the amount of 2.0 mg/mL in A549 cells and Hela cells
were over 90% within 24 h, suggesting good biological
biocompatibility and safety. Compared with free Dox,
Dox-loaded TPP-NPs showed significant higher cytotox-
icity on both cells in a dose-dependent manner, and the
half-maximal inhibitory concentration value of Dox-
loaded TPP-NPs treated A549 cells and Hela cells at
24 h was 13.4 and 10.1 μg/mL, with values of 20.3 μg/
mL in A549 cells and 15.2 μg/mL in Hela cells for free
Dox. These data suggested that Dox encapsulated in
TPP-NPs induced the higher cell inhibition effects, and
this may be because that with the mediation of TPP for
targeting mitochondria, the intracellular distribution of
Dox was located at mitochondria instead of accumulat-
ing at the nucleus, thus significantly improving the
toxicity of Dox in tumor cells.
In Vitro Cellular Uptake
Mitochondrial-targeted ability of Dox-loaded TPP-NPs
and time-lapse imaging of intracellular distribution of
TPP-NPs in A549 cells and Hela cells were observed by
confocal laser scanning microscopy (FluoView FV10i,
Olympus, Japan). Generally, Dox was delivered to nucleus
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and prevented the DNA double helix from being resealed
to inhibit the proliferation of tumor cells; therefore, the
amount of Dox into the nucleus determined the extent of
its antitumor activity. As shown in Fig. 3, when both cells
were incubated with Dox, Dox was gradually accumulated
in the nuclei of tumor cells and the significant higher
red fluorescence emitted by free Dox was focused on
the nucleus, indicating that with the passage of time,
free Dox was effectively transferred into cell nucleus,
thus showing its cytotoxicity. However, when cells were
incubated with Dox-loaded TPP-NPs, red spots were
homogenously distributed in cytoplasm instead of lo-
cating at nucleus, and with the passage of time, the
intracellular red fluorescence became stronger and
TPP-NPs could be sprinkled throughout the whole
cytoplasm. It also demonstrated that in Fig. 3, yellow
dots representing co-localization between the inherent
red fluorescence of Dox encapsulated in TPP-NPs and
the mitochondrial indicator mitotracker® green FM
(green) fluorescence were obviously observed, proving
that our nanocarrier effectively and specifically delivered
its Dox cargo into cell mitochondria and the majority of
TPP-NPs were specifically delivered and accumulated in
the mitochondria of tumor cells.
It can be seen from Fig. 4 that when free Dox and
Dox-loaded TPP-NPs at the same amount of Dox were
treated with both cells, the majority of free Dox had
been internalized into cells with the first 3 h and the up-
take ratio of free Dox was 84.6% in A549 cells and 72.1%
in Hela cells. On the contrary, TPP-NPs showed a slower
internalization process and about 50.4 and 40.8% of all
NPs were transferred into A549 cells and Hela cells
respectively within 3 h. Finally, a majority of NPs accom-
plished their cellular uptake within 6 h. Generally, free
Dox and Dox-loaded TPP-NPs showed a high intracellular
uptake ratio in both cells and there were no obvious
differences on uptake ability between free Dox and Dox-
loaded TPP-NPs.
Fig. 1 Characterization of Dox-loaded TPP-NPs. a TEM image of Dox-loaded TPP-NPs. b DLS analysis of the obtained Dox-loaded TPP-NPs. c In
vitro release profile of Dox-loaded TPP-NPs in phosphate-buffered saline with different pH at 37 °C for 48 h. d FT-IR spectra of TPP-NPs and the
mixture of TPP and CS NPs
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Mitochondrial Membrane Potential Analysis
It was well known that mitochondria was related with
many of the biological activities and especially induced
the significant cell apoptosis effects through the loss of
mitochondrial membrane potential. Mitochondrial dam-
age led to the depolarization of the mitochondria and
caused the decrease of the membrane potential. Changes
of mitochondrial membrane potential of the cells after
treatment with free Dox and Dox-loaded TPP-NPs were
investigated by monitoring the changes of the emitting
fluorescence variation of JC-1 dyes. JC-1, as a cationic
lipophilic dye, could easily penetrate the cell membrane
into the cell and be aggregated in mitochondria with
high respiration activity. The aggregation degree of JC-1
was determined by the membrane potential of mito-
chondria. When cells were in the normal state and the
mitochondrial membrane potential was higher (normal),
the accumulation of JC-1 in the mitochondria was in-
creased and showed red fluorescence. On the contrary,
when the mitochondria were damaged, the membrane
potential was decreased and dye molecule aggregation
was reduced, thus the dye in the state of a single mol-
ecule was dispersed in the cytoplasm and showed green
fluorescence. It could be seen from Fig. 5 that when
both cells were treated with free Dox, dispersed states of
the green fluorescence (JC-1 monomer) and red fluores-
cent dots (JC-1 aggregation) were both observed, sug-
gesting that the JC-1 dye existed in the single molecular
state and the aggregation state. Compared with the weak
green fluorescence from free Dox, the change of the
intracellular fluorescence of JC-1 in cells treated with
Dox-loaded TPP-NPs was observed that red fluorescent
intensity was reduced and the intensity of green fluores-
cence was significantly increased. It also suggested that
when cells were treated with Dox-loaded TPP-NPs, the
aggregation of JC-1 dye as the indicator of undamaged
mitochondrial was reduced and JC-1 monomer as the
indicator of damaged mitochondrial was accumulated.
The mitochondrial membrane potential was decreased
in cells, and the mitochondria in the cells were damaged.
The results proved that Dox-loaded TPP-NPs induced
the targeted delivery of Dox into mitochondria and
significantly enhanced the damage of mitochondria by
reducing the mitochondrial membrane potential.
ROS Determination
The latest study found that ROS played an important
role in regulating the process of cell apoptosis, and ROS
generation led to mitochondrial swelling and the formation
of unspecific channel in mitochondria, thus resulting in
Fig. 2 Viability of A549 cells (a) and Hela cells (b) after incubation with different amounts of naked NPs for 24 h (n = 3). Data are presented as
means ± SD (n = 3). c A549 cells viability cultured with Dox-loaded TPP-NPs and free Dox at different concentrations of Dox after 24 h. Data
are presented as means ± SD (n = 3). #P < 0.05 vs the corresponding free Dox. d Hela cells viability cultured with Dox-loaded TPP-NPs and free
Dox at different concentrations of Dox after 24 h. Data are presented as means ± SD (n = 3). *P < 0.05 vs the corresponding free Dox
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Fig. 3 In vitro cellular distribution of NPs after incubating different tumor cells with free Dox and Dox-loaded TPP-NPs. Fluorescent image of A549
(a) and Hela cells (b), the scale bar is 50 μm and applies to all parts
Fig. 4 Fluorescence spectrum quantitative analysis of free Dox and Dox-loaded TPP-NPs in A549 (a) and Hela cells (b). Data are presented as
means ± SD (n = 3). *P < 0.05 vs Dox-loaded TPP-NPs treated with cells at 3 h
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Fig. 5 Imaging change of mitochondrial membrane potential after incubating free Dox and Dox-loaded TPP-NPs with A549 cells and Hela cells,
the scale bar is 50 μm and applies to all parts
Fig. 6 Quantification of ROS generation in cells treated with free Dox and Dox-loaded TPP-NPs at different time. a A549 cells. b Hela cells. Data
are presented as means ± SD (n = 3). +P < 0.05 vs control group at 12 h, *P < 0.05 vs control group at 24 h, #P < 0.05 vs control group at 48 h
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the significant decrease of the potential of mitochondrial
membrane and further inducing the rapid release of the
apoptosis-induced factor and the cytochrome c from mito-
chondria, finally leading to a series of apoptotic responses.
The results (Fig. 6) demonstrated that after treated with
free Dox and Dox-loaded TPP-NPs, the generation of ROS
in A549 cells and Hela cells was significantly changed.
Figure 6a, b demonstrated that ROS levels in A549 cells
and Hela cells exposed to free Dox showed a certain
enhancement and were increased to 120.5% in 24 h and
130.4% in 48 h in A549 cells in comparison with 130.4%
in 24 h and 136.7% in 48 h in Hela cells. Similarly, Dox-
loaded TPP-NPs also triggered the augment of ROS levels
at 168.4% in 24 h and 180.4% in 48 h in A549 cells, and
150.1% in 24 h and 166.5% in 48 h in Hela cells.
Western Blot Analysis
It was found that the dysfunction of mitochondria
often resulted in cell death, and some mitochondrial
apoptosis-related proteins, such as cytochrome c and
apoptosis-related proteins, were often regulated. The
targeted distribution of Dox in mitochondria induced
the rapid release of the apoptosis-inducing factor and
the cytochrome c from mitochondria. As shown in
Fig. 7, it demonstrated that compared with free Dox,
Dox-loaded TPP-NPs with the same concentration of
Dox showed the significant enhancement on the ex-
pression levels of apoptosis-related proteins such as
Bax, caspase-9, and caspase-3, and more cytochrome
c were released rapidly from mitochondria into the
cytoplasm. It suggested that when Dox was selectively
accumulated into mitochondria with the mediation of
TPP-NPs, pro-apoptotic protein Bax was activated
and the mitochondrial membrane potential was dissi-
pated and further disrupted mitochondrial membrane
integrity. Finally, cytochrome c was released rapidly
from the mitochondria into cytoplasm and initiated
the activation of apoptosis-related proteins such as
caspase-9 and caspase-3, eventually inducing signifi-
cant apoptosis of tumor cells.
Discussion
Here, we designed a new functional nanoparticle system
for enhancing drug accumulation in the mitochondria
and leading to the significant apoptosis of cancer cells.
The cytotoxicity of Dox caused by the targeted accumu-
lation of Dox mediated by TPP-NPs was enhanced by
activating the mitochondria signaling pathway in cancer
cells, demonstrating increased activity and the rapid
release of cytochrome c, caspase-9, and caspase-3. In
order to achieve targeted drug delivery to mitochon-
dria, the cationic lipophilic compound triphenyl phos-
phine (TPP) had been conjugated to nanoparticles. The
results showed that Dox-loaded TPP-NPs were spher-
ical in shape and dispersed homogenously with lower
polydispersity index. Dox-loaded TPP-NPs showed sus-
tained release of Dox from nanoparticles and with the
decrease of pH in medium; the releasing rate of Dox
was increased and the cumulative release of drug was
significantly enhanced. At the same time, compared
with targeted location of free Dox in nucleus, when
cells were incubated with Dox-loaded TPP-NPs, red
spots representing Dox were homogenously distributed
in mitochondria instead of location at nucleus. The
mitochondrial membrane potential was decreased in
cells and the mitochondria in the cells were almost
completely damaged. After treated with free Dox and
Dox-loaded TPP-NPs, the generation of ROS in A549
cells and Hela cells was significantly enhanced, suggest-
ing induction of ROS for triggering the cell apoptosis.
Taken together, Dox-loaded TPP-NPs increased the
mitochondrial delivery of Dox, therefore increasing
cytotoxicity of drug and inducing the significant apop-
tosis effect.
Fig. 7 Western blot analyses of the expression levels of caspase-3, caspase-9, Bax, and cytochrome c in Hela cells
Hou et al. Nanoscale Research Letters  (2017) 12:158 Page 8 of 9
Conclusions
We had constructed a mitochondrial-targeted functional
nanoparticle delivery system for enhancing antitumor ef-
ficiency. The cationic lipophilic compound triphenyl
phosphine (TPP) with high mitochondrial binding speci-
ficity was introduced, and broad-spectrum anticancer
drug Dox was entrapped in the cavity of nanoparticles
for achieving the better physiological functions. It
showed that Dox-loaded TPP-NPs were internalized into
the cytoplasm and further quickly located at the mito-
chondria to release Dox with the mediation of TPP-NPs.
Dox in mitochondria activated the mitochondrial apop-
totic pathway, reduced mitochondrial membrane poten-
tial, and opened mitochondrial membrane hole, thus
releasing cytochrome c and promoting expression of
Bax, caspase-3, and caspase-9. Taken together, triphenyl
phosphine-conjugated chitosan nanoparticles provided
preferential mitochondrial delivery and accumulation of
Dox, thus improving drug efficacy in tumor cells.
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